Formulation and Evaluation of Dry Powder Inhaler Containing Inhaled Carticosteroids and Long Acting Beta Agonist of Different Fill Weight

Abstract

The overall objective of this research project was to study the in DPI formulations containing ICH and LABA to achieve efficient drug deposition goals. Hence, this project focused on the formulation development of DPIs and impact of different fill weight or fill volume in performance as well as other physicochemical parameter. The performance mainly APSD of dry powder inhalers containing LABA & ICS was found to be optimum when it is formulated with 30% of fine grade lactose monohydrate. The APSD evaluation was concluded that the deposition of particle of (F8) 12.5 mg is better than (F4) 25 mg. It’s may due to more void space in the 12.5 mg capsule formulation than 25 mg capsule formulation. Due to this good turbulence occurs and separation drug particle form carrier surface is more and give better deposition compared to 25 mg fill weight formulation per capsule. The overall project concluded the 12.5mg formulation (F8) is good. These formulations are advantages over 25 mg formulation such as less carrier residue, cost effective, good therapeutic result.